WeissLaw LLP Investigates Juniper Pharmaceuticals, Inc.

NEW YORK, July 5, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Juniper Pharmaceuticals, Inc. ("JNP" or the "Company") (NASDAQ: JNP) in connection with the proposed acquisition of the Company by Catalent Inc. ("CTLT) (NYSE: CTLT).  Under the terms of the acquisition agreement, JNP shareholders will receive $11.50 in cash for each share they own.   

WeissLaw is investigating whether JNP's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, the per-share offer price is $8.50 less than the analyst target price of $20.00. 

Additionally, JNP reported record results in its latest financial release.  On May 10, 2018, the Company reported an impressive 30% annual increase in revenues for its progesterone gel, CRINONE, and a remarkable increase of 55% year-over-year for revenues relating to its Juniper Pharma Services.  

Finally, the deal is a strategic transaction which CTLT hopes to leverage to improve its market positioning.  According to the President of CTLT's Oral Drug Delivery, "[JNP's] expertise and capabilities in pharmaceutical services will further support [CTLT's] strategic goal to be the comprehensive partner of choice for pharmaceutical innovators. . . . [JNP]'s proven scientific expertise in early-phase product development and supply-chain management will help our customers unlock the full potential of their molecules and provide better treatments to patients, faster."

Given these facts, WeissLaw is investigating whether JNP's Board acted in the best interests of JNP's public shareholders to maximize shareholder value prior to entering into the agreement.  If you own JNP shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubin by telephone at [phone] or by email at [e-mail].  

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [e-mail] or fill out the form on our website, http://www.weisslawllp.com/juniper-pharmaceuticals-inc/

View original content:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-juniper-pharmaceuticals-inc-300676767.html

SOURCE WeissLaw LLP

Copyright 2018 PR Newswire